Challenges facing drug development for malaria

Current Opinion in Microbiology

Volumn 11, Issue 5, 2008, Pages 428-433

  Craft, J Carl ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ; ARTESUNATE; ATOVAQUONE PLUS PROGUANIL; CHLOROQUINE; CHLORPHENOTANE; DIHYDROARTEMISININ PLUS PIPERAQUINE; DOXYCYCLINE; FANSIDAR; FERROQUINE; MEFLOQUINE; PRIMAQUINE; PYRONARIDINE; TAFENOQUINE; UNCLASSIFIED DRUG;

BED NET; CAUSE OF DEATH; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; FUNDING; GAMETOCYTE; HUMAN; INFECTION PREVENTION; MALARIA; MALARIA CONTROL; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; PHARMACIST; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; POINT MUTATION; PREGNANT WOMAN; REVIEW; TERATOGENICITY;

ANIMALS; ANTIMALARIALS; DEVELOPING COUNTRIES; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; HUMANS; MALARIA; PLASMODIUM;

EID: 55049131325     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mib.2008.09.003     Document Type: Review

References (59)

1. Rowe A.K., Rowe S.Y., Snow R.W., Korernromp E.L., SchellenbergJ, Stein C., Nahlen B.L., Bryce J., Black R.E., and Steketee R.W. The burden of malaria mortality among African children in the year 2000. Int J Epidemiol 35 (2006) 691-704
2. Becker H., Kynast-Wolf G., Sié A., Ndugwa R., Ranroth H., Kouyaté B., and Müller O. Patterns of malaria: cause-specific and all-cause mortality in a malaria-endemic area of West Africa. Am J Trop Med Hyg 1 (2008) 106-113
3. Garenne M., and Gakusi E. Health transitions in sub-Saharan Africa: overview of mortality trends in children under 5 years old (1950-2000). Bull World Health Organ 84 (2006) 470-478
4. Lopez A.D., Mathers C.D., Ezzati M., Jamison D.T., and Murry C.J. Global and regional burden of disease and risk factors 2001: systemic analysis of population health data. Lancet 367 (2006) 1747-1757
5. Borrmann S., Matsiegui P.-B., Missinou M.A., and Kremsner P.G. Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcome of antimalarial treatment in children. Antimicrob Agents Chemother 5 (2008) 1799-1805
6. Dondorp A.M., Lee S.J., Faiz M.A., Mishra S., Price R., Tjitra E., Than M., Htut Y., Mohanty S., Yunus E.B., et al. The relationship between age and the manifestations of and mortality associated with severe malaria. CID 47 (2008) 151-157
7. Olliaro P. Editorial Commentary: mortality associated with severe Plasmodium falciparum malaria increases with age. CID 47 (2008) 158-160
8. Hasting I.M., Korenromp E.L., and Bloland P.B. The anatomy of a malaria disaster: drug policy choice and mortality in African children. Infection, The Lancet 7 (2007) 739-748
9. Goller J.L., Jolley D., Ringwald P., and Biggs B.A. Regional differences in the response of Plasmodium vivax malaria to primaquine as anti-relapse therapy. Am J Trop Med Hyg 2 (2007) 203-207
10. Rungsihirunrat K., Ba-Bangchang K., Hawkins V.N., Mungthin M., and Sibley C.H. Sensitivity to antifolates and genetic analysis of Plasmodium vivax isolates from Thailand. Am J Trop Med Hyg 6 (2007) 1057-1065
11. Stepniewska K., and White N.J. Pharmacokinetics determinants of the window of selection for antimalarial drug resistance. Antimicrob Agents Chemother 5 (2008) 1589-1596. Using pharmacokinetic modeling the author discusses the effects of pharmacokinetics on the potential to develop resistance.
12. Hastings L.M. Complex dynamics and stability of resistance to antimalarial drugs. Parasitology 132 (2006) 615-624
13. Alker A.P., Lim P., Sem R., Shah N.K., Yi S.P., Bouth D.M., Tsuyuoka R., Maguire J.D., Fandeur T., Ariey F., et al. PFMDR1 and in vivo resistance to artesunate-mefloquine in Falciparum malaria on the Cambodian-Thai border. Am J Trop Med Hyg 4 (2007) 641-647
14. Mehlotra R.K., Mattera G., Bockarie M.J., Maguire J.D., Baird J.K., Sharma Y.D., Alifrangis M., Dorsey G., Rosenthal P.J., Fryauff D.J., et al. Discordant patterns of genetic variation at two chloroquine resistance loci in worldwide populations of the malaria parasite Plasmodium falciparum. Antimicrob Agents Chemother 6 (2008) 2212-2222
15. Lynch C., Pearce R., Pota H., Cox J., Abeku T.A., Rwakimari J., Naidoo I., Tibenderana J., and Roper C. Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum population from Southwest Uganda. JID 197 (2008) 1598-1604
16. Japrung D., Leartsakulpanich U., Chusacultanachai S., and Yuthavong Y. Conflicting requirements of Plasmodium falciparum dihydrofolate reductase mutations conferring resistance to pyrimethamine-WR99210 combination. Antimicrob Agents Chemother 12 (2007) 4356-4360
17. Tinto H., Ouédraogo J.B., Zongo I., Van Overmeir C., Van Marck E., Guiguemdé T.R., and D'Alessandro. Sulfadoxine-pyrimethamine efficacy and selection of Plasmodium falciparum DHFR mutations in Burkina Faso before its introduction as intermittent preventive treatment for pregnant women. Am J Trop Med Hyg 4 (2007) 608-613
18. Barnes K.I., Little F., Mabuza A., Mngomezulu N., Govere J., Durrheim D., Roper C., Watkins B., and White N.J. Increased gametocytemia after treatment: an early parasitological indicator of emerging sulfadoxine-pyrimethamine resistance in falciparum malaria. JID 197 (2008) 1605-1613
19. R08 Wongsrichanalai C., and Meshnick S.R. Declining artesunate-mefloquine efficacy against Falciparum malaria on the Cambodia-Thailand border. Emerg Infect Dis 5 (2008) 716-719. Artemesinins are the only anti-malarials that have not shown resistance and are the main stay of ACTs. The observations declining activity on the Cambodia-Thailand border is on grave concern.
20. Hall K.A., Newton P.N., Green M.D., de Veij M., Vandenabeele P., Pizzanelli D., Mayxay M., Dondorp A., and Fernandez F.M. Characterization of counterfeit artesunate antimalarial tablets from Southeast Asia. Am J Trop Med Hyg 5 (2006) 804-811. Counterfeit drugs kill and are probably a cause of drug resistance. The authors demonstrate the lengths to which the counterfeiters go to fool the consumers.
21. Baird J.K. A rare glimpse at the efficacy of primaquine. Am J Trop Med Hyg 2 (2007) 201-202
22. Ratsimbasoa A., Randriamantena A., Raherinjafy R., Rasoarilalao N., and Ménard D. Which malaria rapid test for Madagascar? Field and Laboratory evaluation of three test and expert microscopy of samples from suspected malaria patients in Madagascar. Am J Trop Med Hyg 3 (2007) 481-485
23. Rakotonirina H., Barnadas C., Raherijafy R., Andrianantenaina H., Ratsimbasoa A., Randrianasolo L., Jahevitra M., Andriantsoanirina V., and Ménard D. Accuracy and reliability of malaria diagnostic techniques for guiding febrile outpatient treatment in malaria-endemic countries. Am J Trop Med Hyg 2 (2008) 217-221
24. Vinety J.M. Editorial commentary: emerging chloroquine-resistant Plasmodium vivax (benign tertian) malaria: the need for alternative drug treatment. CID 42 (2006) 1073-1074
25. Imwong M., Snounou G., Pukrittayakamee S., Tanomsing N., Kim J.R., Nandy A., Guthmann J.-P., Nosten F., Carlton J., Looareesuwan S., et al. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnoyoites. JID 195 (2007) 927-933
26. Hasting I.M., Korenromp E.L., and Boland P.B. The anatomy of a malaria disaster: drug policy choice and mortality in African children. Infection, The Lancet 7 (2007) 739-748
27. Parola P., Pradines B., Simon F., Carlotti M.P., Minodier P., Ranjeva M.P., Badiaga S., Bertaux L., Delmont J., Morillon M., et al. Antimalarial drug susceptibility and point mutations associated with drug resistance in 248 Plasmodium falciparum isolates imported from Comoros to Marseille, France in 2004-2005. Am J Trop Med Hyg 3 (2007) 431-437
28. ter Kuile F.O., van Eijk A.M., and Filler S.J. Effect of sulfadoxine-pyrimethamine resistance on the efficacy of intermittent preventive therapy for malaria control during pregnancy. JAMA 23 (2007) 2603-2616
29. Aweeka F.T., and German P.I. Clinical pharmacology of artemisinin-based combination therapies. Clin Pharmacokinet 2 (2008) 91-102. A good review of the thinking that went into the choices for artemisinin combination drugs.
30. Hatz C., Soto J., Nothdurft H.D., Zoller T., Weitzel T., Loutan L., Bricaire F., Gay F., Burchard G.-D., Andriano K., et al. Treatment of acute uncomplicated Falciparum malaria with artesunate-lumefantrine in non-immune populations: a safety, efficacy, and pharmacokinetic study. Am J Trop Med Hyg 2 (2008) 241-247
31. Thapa S., Hollander J., Linehan M., Cox-Singh J., Bista M.B., Thakur G.D., Davis W.A., and Davis T.M. Comparison of artemether-lumefantrine with sulfadoxine-pyrimethamine for the treatment of uncomplicated Falciparum malaria in Eastern Nepal. Am J Trop Med Hyg 3 (2007) 423-430
32. Sowunmi A., Gbotosho G.O., Happi C.T., Adedeji A.A., Fehintola F.A., Folarin O.A., Tambo E., and Fateye B.A. Therapeitic efficacy and effects of artemether-lumefantrine and amodiaquine-sulfalene-pyrimethamine on gametocyte carriage in children with uncomplicated Plasmodium falciparum malaria in Southwestern Nigeria. Am J Trop Med Hyg 2 (2007) 235-241. This study shows the improved efficacy of artemisinin, containing combinations therapy over a NACT, particularly in regard to transmission-blocking activity.
33. Hasuian A.R., Purba L.E., Kenangalem E., Wuwung R.M., Ebsworth E.P., Maristela R., Penttinen P.M.P., Laihad F., Anstey N.M., Tjitra E., and Price R.N. Dihydroartemisinin-piperaquine versus artesunated amodiaquine: Superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodiun vivax malaria. CID 44 (2007) 1067-1074
34. Vivas L., Rattray L., Stewart L., Bongard E., Robinson B.L., Peters W., and Croft S.L. Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Tropica 1 (2007) 69-77
35. Kreidenweiss A., Kremsner P.G., Dietz K., and Mordmüller B. In vitro activity of ferroquine (SAR97193) is independent of chloroquine resistance in Plasmodium falciparum. Am J Trop Med Hyg 6 (2006) 1178-1181
36. Mishra S.K., Mohanty S., Mohanty A., and Das B.S. Management of severe and complicated malaria. J Postgrad Med 52 (2006) 281-287
37. Krudsood S., Tangpukdee N., Wilairatana P., Phophak N., Baird J.K., Brittenham G.M., and Looareesuwan S. High-dose primaquine regimens against relapse of Plasmodium vivax malaria. Am J Trop Med Hyg 5 (2008) 736-740. This study looked as high dose primaquine in radical cures of P. vivax. It points out that higher doses than recommended in the past may be needed to insure a radical cure in P. vivax malaria.
38. Kitchener S., Nasveld P., and Edstein M.D. Short report: Tafenoquine for the treatment of recurrent Plasmodium vivax malaria. Am J Trop Med Hyg 3 (2007) 494-496
39. Tukur I.U., Thacher T.D., Sagay A.S., and Madaki J.K.A. A comparison of sulfadoxine-pyrimethamine with chloroquine and pyrimethamine for prevention of malaria in pregnant Nigerian women. Am J Trop Med Hyg 6 (2007) 1019-1023
40. Ramharter M., Schuster K., Bouyou-Akotet M.K., Adegnika A.A., Schmits K., Mombo-Ngoma G., Agnandji S.T., Nemeth J., Afène S.N., Issifou S., et al. Malaria in pregnancy before and after the implementation of a national IPTp program in Gabon. Am J Trop Med Hyg 3 (2007) 418-422
41. Ntab B., Cissé B., Boulanger D., Sokhna C., Targett G., Lines J., Alexander N., Trape J.F., Simondon F., Greenwood B.M., and Simondon K.B. Impact of intermittent preventive anti-malarial treatment on the growth and Nutritional status of preschool children in rural Senegal (West Africa). Am J Trop Med Hyg 3 (2007) 411-417
42. Kobbe R., Kreuzberg C., Adjei S., Thompson B., Langefeld I., Thompson P.A., Abruquah H.H., Kreuels B., Ayim M., Busch W., et al. A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clin Infect Dis 45 (2007) 16-25
43. Senn N., D'Acremont V., Landry P., and Genton B. Malaria chemoprophylaxis: what do the travelers choose, and how does pretravel consultation influence their final decision. Am J Trop Med Hyg 6 (2007) 1010-1014
44. Polhemus M.E., Remich S., Ogutu B., Waitumbi J., Lievens M., Ballou W.R., and Heppner. Malaria treatment with atovaquono-proguanil in malaria-immune adults: implications for malaria intervention trials and for pre-exposure prophylaxis of malaria. Antimicrob Agents Chemother 4 (2008) 1493-1495
45. Yeates C.L., Batchelor J.F., Capon E.C., Cheesman N.J., Fry M., Hudson A.T., Pudney M., Trimming H., Woolven J., Bueno J.M., et al. Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials. J Med Chem 3 (2008) 449-457
46. Creek D.J., Charman W.N., Chiu F.C.K., Prankerd R.J., Dong Y., Vennerstrom J.L., and Charman S. Relationship between antimalarial activity and heme alkylation for spiro- and dispiro-1,2,4-troxolane antimalarials. Antimicrob Agents Chemother 4 (2008) 1291-1296
47. Dietmann A., Helbok R., Lackner P., Issifou S., Lell B., Matsiegui P.-B., Reindl M., Schmutzhard E., and Kremsner P.G. Matrix metalloproteinases and their tissue inhibitors (TIMPs) in Plasmodium falciparum malaria: serum levels of TIMP-1 are associated with disease severity. JID 197 (2008) 1614-1620
48. Andrews K.T., Tran T.N., Lucke A.J., Kahnberg P., Le G.T., Boyle G.M., Gardiner D.L., Skinner, Adams T.S., and Fairlie D.P. Potent antimalarial activity of histone deacetylase inhibitor analogues. Antimicrob Agents Chemother 4 (2008) 1454-1461
49. Mahmoudi N., Garcia-Domenech R., Galvez J., Farhati K., Franetich J.-F., Sauerwein R., Hannoun L., Derouin F., Danis M., and Mazier D. New active drugs against liver stages of Plasmodium predicted by molecular topology. Antimicrob Agents Chemother 4 (2008) 1215-1220
50. Plowe C.V. Editorial commentary: combination therapy for malaria: mission accomplished. CID 44 (2007) 1075-1077
51. Stepniewska K., and White Nick. Some considerations in the design and interpretation of antimalarial drug trials in uncomplicated falciparum malaria. Malaria J 5 (2006) 1-15
52. White N.J. Qinghaosu (artemisinin): the price of success. Science 320 (2008) 330-334
53. White J.W. Editorial: clinical trials in tropical diseases: a politically in correct view. Tropical Med Int Health 11 (2006) 1483-1484
54. Taylor W.R.J., Terlouw D.J., Olliaro P.L., White N.J., Brasseur P., and ter Kuile F.O. Use of weight-for-age-data to optimize tablet strength and dosing regimens for a new fixed-dose artesunate-amodiaquine combination for treat falciparum malaria. Bull World Health Organ 12 (2006) 956-964
55. Boareto A.C., Muller J.C., Bufalo A.C., Botelho G.G.K., de Araujo S.L., Foglio M.A., de Morais R.N., and Dalsenter P.R. Toxicity of artemisinin [artemisia annua L.] in two different periods of pregnancy in Wister rats. Reprod Toxicol 25 (2008) 239-246
56. White T.E.K., Bushdid P.B., Ritter S., Laffan S.B., and Clark R.L. Artesunate-induced depletion of embryonic erythroblasts precedes embryolethality and teratogenicity in vivo. Birth Defects Res (Part B) 77 (2006) 413-429
57. Feachem R., and Sabot O. A new global malaria eradication strategy. The Lancet 371 (2008) 1633-1635
58. Chotivanich K., Sattabongkot J., Udomsangpetch R., Looareesuwan S., Day N.P.J., Coleman R.E., and White N.J. Transmission-blocking activities of quinine, primaquine and artesunate. Antimicrob Agents Chemother 6 (2006) 1927-1930
59. Campbell C.C. Perspectives: halting the toll of malaria in Africa. Am J Trop Med Hyg 6 (2008) 851-853